{"id":33846,"date":"2025-02-11T12:07:00","date_gmt":"2025-02-11T12:07:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4616506_AE16506_0"},"modified":"2025-02-11T12:07:00","modified_gmt":"2025-02-11T12:07:00","slug":"ziwig-endotest-fast-track-reimbursement-for-25-000-patients-for-first-saliva-test-to-diagnose-endometriosis-in-80-medical-centers-in-france","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=33846","title":{"rendered":"ZIWIG ENDOTEST\u00ae: FAST-TRACK REIMBURSEMENT FOR 25 000 PATIENTS FOR FIRST SALIVA TEST TO DIAGNOSE ENDOMETRIOSIS IN 80 MEDICAL CENTERS IN FRANCE"},"content":{"rendered":"\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

LYON, France<\/span><\/span>, Feb. 11, 2025<\/span><\/span> \/PRNewswire\/ — Ziwig, a French biotech company committed to advancing women’s health, announces the fast-track reimbursement of Ziwig Endotest\u00ae – the first saliva diagnostic test for endometriosis- for 25 000 patients across 80 medical centers in France<\/span> thanks to the Innovation Funding Feb 11<\/span> decree.<\/p>\n

\"Ziwig<\/a>
Ziwig Endotest\u00ae<\/span> <\/div>\n

French health authorities take a major step towards improving diagnosis of endometriosis by fast-tracking reimbursement for patients for Ziwig Endotest\u00ae a reliable and non-invasive diagnosis tool with results available within a few days.<\/p>\n

Endometriosis affects 1 in 10 women worldwide. The variety and scope of symptoms can significantly alter women’s health, quality of life and fertility. Ending medical wandering \u2013evaluated between 7 to 10 years\u2013 is key to improve care, quality of life and fertility.<\/p>\n

About Ziwig Endotest\u00ae<\/b><\/p>\n

Ziwig Endotest\u00ae has demonstrated 97,4% sensitivity and 93,5% specificity in detecting all forms of endometriosis including early peritoneal endometriosis.<\/p>\n

Ziwig Endotest\u00ae is a breakthrough biological test for practitioners and patients by:<\/p>\n